British molecular imaging company Blue Earth Diagnostics has agreed to be acquired by Italian diagnostic imaging company Bracco Imaging in a deal valued at $450 million.
Bracco Imaging will buy Blue Earth Diagnostics from healthcare company Syncona in a transaction which also includes an additional closing adjustment of around $25 million.
Blue Earth’s innovative products and pipeline will enhance Bracco’s portfolio in precision medicine and personalised diagnostics while extending its range of nuclear oncology imaging solutions in the Urology segment and other specialties.
On completion of the deal, expected to occur in the third quarter of 2019 subject to customary closing conditions, Blue Earth will become a subsidiary of Bracco while retaining both its leadership team and its own brand name.